-+ 0.00%
-+ 0.00%
-+ 0.00%
Sedana Medical Q3 operating loss widens 36% year over year to SEK 14.5 million; Q3 net sales rise 7% year over year to SEK 44.2 million
Share
Listen to the news
Sedana Medical Q3 operating loss widens 36% year over year to SEK 14.5 million; Q3 net sales rise 7% year over year to SEK 44.2 million
  • Sedana Medical’s third-quarter 2026 net loss narrowed 10% year over year to SEK 11.1 million.
  • Net sales rose 7% year over year to SEK 44.2 million, while operating loss widened 36% to SEK 14.5 million.
  • The FDA accepted its New Drug Application for review, setting a target decision date of April 16, 2027.
  • Management reaffirmed expectations to meet full-year financial guidance.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sedana Medical AB published the original content used to generate this news brief on October 22, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending